Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Company facts
| Company | Eli Lilly and Company |
|---|---|
| Symbol | LLY |
| Exchange | XNYS |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market cap | $1.00T (Massive market data, 2026-09-10) |
| Employees | 50,000 |
| Country | United States |
| Website | https://www.lilly.com |
Trading — Eli Lilly and Company
| Last price | $1,115.70 |
|---|---|
| Change | -0.65% |
| Previous close | $1,123.00 |
| Day range | $1,113.29 – $1,131.44 |
| 50-day average | $1,186.18 |
| 200-day average | $1,064.57 |
| Average volume | 3,232,139 |
Price basis: yfinance_daily_bar_close · 2026-09-11T20:31:40.505291+00:00
Valuation and financial health
| Earnings per share | $29.97 |
|---|---|
| Price / book | 29.55 |
| Price / cash flow | 35.64 |
| Enterprise value / EBITDA | 25.10 |
| Enterprise value / sales | 13.14 |
| Debt / equity | 1.62 |
| Current ratio | 1.35 |
| Dividend yield | 0.58% |
| Free cash flow | $18.19B |
| Cash ratio | 0.19 |
| Enterprise value | $1.05T |
Reported 2026-09-10
Earnings
| Report date | 2026-10-29 |
|---|---|
| Session | Pre Market |
| Fiscal quarter ending | Sep/2026 |
| EPS estimate | $9.56 |
| Year-ago EPS | $7.02 |
| Analyst estimates | 4 |
Source: Nasdaq.com public earnings calendar
Other Healthcare companies
Live data
Live quotes, options positioning, insider and congressional filings for LLY are on the IntelTrends dashboard.